Regeneron wins FDA approval for first treatment of rare bone-forming disease
The FDA cleared Regeneron's garetosmab, an antibody targeting activin A, for fibrodysplasia ossificans progressiva, a condition where muscle and connective tissue progressively turn to bone. This marks the first approved therapy for the debilitating disorder.
The approval marks a turning point for fibrodysplasia ossificans progressiva, a genetic disorder in which soft tissues ossify after injury or inflammation. Garetosmab works by neutralizing activin A, a protein implicated in abnormal bone formation. Because no prior therapy existed, patients faced progressive immobility and shortened lifespans. Regeneron’s antibody now offers a targeted intervention, though long-term effects remain under study. The decision follows years of research into rare skeletal diseases, highlighting how biologics can address conditions once deemed untreatable.
This approval could reshape care for a small but severely affected patient community, offering hope for slowing disease progression. It may also encourage investment in ultra-rare disease research, as regulatory pathways now favor targeted biologics. However, access and cost could limit widespread benefit, and long-term safety data will be crucial. Clinicians and patients may need to balance early treatment against unknown risks, potentially influencing how future rare-disease therapies are evaluated and adopted.